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Abstract: The recent development of once-daily antiretroviral agents and fixed-dose combination 
formulations has been an important development in antiretroviral regimen   simplification. 
Recent studies indicate that once-daily antiretroviral regimens improve adherence, especially 
in antiretroviral-naïve patients and in difficult-to-treat populations, such as the homeless or 
marginally housed. However, there are potential risks with the higher peak and lower trough 
plasma drug concentrations that may result from certain once-daily formulations. Due to the 
multifactorial and complex nature of adherence behavior, clinicians’ efforts to improve patient 
adherence should not be limited to prescribing once-daily regimens, but should also consider 
social support, side effect management, and adherence support tools, such as pillbox organiz-
ers and other targeted interventions. Additional research will clarify the benefits of once-daily 
and fixed-dose combination regimens on clinical and virologic outcomes. Comprehensive 
cost-benefit analysis of regimen simplification could help facilitate evidence-based decisions 
regarding antiretroviral regimen choices.
Keywords: regimen adherence, regimen simplification, health care costs, fixed-dose 
combination, once-daily antiretroviral drugs
Antiretroviral regimen simplification:  
a moving target
The simplification of antiretroviral regimens has the potential to improve long-term 
adherence, virologic efficacy, and clinical outcomes.1 Simplification strategies that 
employ antiretroviral agents that are currently approved or under study include use 
of once-daily dosing regimens, better tolerated or less toxic regimens, fixed-dose 
coformulations, and induction-maintenance approaches (Table 1).2 In this brief 
narrative review, we will focus on the following: results from published clinical 
studies (both randomized and observational) that directly compare twice-daily versus 
once-daily regimens; the clinical benefits and possible risks to the patient with once-
daily regimens; the costs and benefits associated with better adherence when using once-
daily regimens; and the ongoing research agenda for evidence-based improvements 
to simplified regimens.
Multiple studies have demonstrated that adherence to antiretroviral therapeutic 
regimens is among the most powerful predictors of sustained virologic suppression, 
reduced risk of developing drug resistance, limited disease progression, and improved 
patient survival.3–8 Since simpler antiretroviral regimens are considered easier to   follow 
and result in improved patient adherence, over the last decade the trend has been to 
simplify treatment regimens.9 The key objectives of this strategy are to reduce the 
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overall pill burden (from .2–5 daily to one daily) and the 
number of times per day pills must be taken (eg, from three 
times daily to once daily) while maintaining virologic   efficacy 
and treatment tolerability.10,11
Data from randomized controlled trials are necessary to 
confirm whether the benefits of these simplified regimens 
extend beyond improved adherence. Treatment simplification 
with older antiretroviral regimens (eg, didanosine/tenofovir, 
abacavir/zidovudine/lamivudine) did not result in improved 
virologic efficacy.12–14 However, a more recent observational 
study involving patients with limited social support 
(eg, homeless or marginally housed patients) found that 
a once-daily fixed-dose combination regimen (efavirenz/
emtricitabine/tenofovir) significantly improved adherence 
(P = 0.006) and viral suppression (human immunodeficiency 
virus [HIV] RNA , 50 copies/mL: 69.2% vs 46.5%; 
P = 0.02) when compared with a historical control 
group using multiple-dose antiretroviral regimens.15 
The fixed-dose combination of efavirenz/tenofovir/
emtricitabine is a Department of Health and Human 
Services preferred first-line antiretroviral regimen based 
on sustained non-inferior virologic efficacy compared with 
ritonavir (r)-boosted protease inhibitors (eg, darunavir/r, 
atazanavir/r), and raltegravir-based and maraviroc-based 
regimens.16–18 The success of efavirenz/emtricitabine/
tenofovir in the marketplace has led to the development 
of other single-pill once-daily coformulated regimens 
(eg, rilpivirine/emtricitabine/tenofovir and elvitegravir/
cobicistat/emtricitabine/tenofovir).
The immediate-release formulation of nevirapine was 
approved for twice-daily dosing, which is less than ideal if the 
background regimen is taken on a once-daily basis. Because 
nevirapine immediate-release has a long half-life, once-daily 
dosing was initially explored, but this dosing regimen was 
associated with an increased risk of hepatitis.19
A new extended-release formulation of nevirapine 
(  Viramune® XR™) has been approved for once-daily dosing 
by the US Food and Drug Administration,20 based principally 
on the results of the recent VERxVE study, a double-blind, 
double-dummy randomized clinical trial comparing the 
efficacy and safety of nevirapine extended-release (once 
daily) with nevirapine immediate-release (twice daily) in 
HIV treatment-naïve adults (n = 1011).21 The nevirapine 
extended-release formulation was found to have noninferior 
efficacy compared with the nevirapine immediate-release 
formulation, (both in combination with tenofovir and 
emtricitabine).21 The safety and adverse event profiles of the 
two formulations were also similar.21 The new nevirapine 
extended-release formulation provides an additional once-
daily regimen option for clinicians and their patients, in 
keeping with once-daily nucleoside reverse transcriptase 
inhibitor background agents (eg, tenofovir/emtricitabine) 
that are widely used.
In summary, the development of new antiretroviral 
formulations that enable simplification of treatment regimens 
is essential to meet the medical objective of better adherence 
by utilizing once-daily antiretrovirals.
Once-daily versus twice-daily  
dosing regimens
A limited number of studies in the past have addressed 
improving treatment adherence with once-daily dosing 
regimens in varied patient populations. In general, these 
reports agree with the hypothesis that patients demonstrate 
better adherence when using once-daily regimens. In a 
meta-analysis of 11 randomized controlled trials involving 
a total of 3029 subjects, the impact of once-daily regimens 
on treatment adherence was evaluated. Adherence rates were 
modestly better with once-daily regimens (+2.9%, 95% 
confidence interval [CI]: 1.0%–4.8%; P , 0.003) than with 
twice-daily regimens,11 providing support for the use of once-
daily regimens to help improve patient adherence. However, 
week 48 treatment outcomes as measured by virologic 
suppression were comparable between once-daily versus 
Table 1 Antiretroviral fixed-dose combinations
FDA-approved Type
AZT/3TC Dual NRTI
d4T/3TC* Dual NRTI
ABC/3TC Dual NRTI
TDF/FTC Dual NRTI
TDF/3TC* Dual NRTI
AZT/3TC/NVP* NNRTI + dual NRTI
d4T/3TC/NVP* NNRTI + dual NRTI
AZT/3TC/ABC Triple NRTI
TDF/FTC/EFV NNRTI + dual NRTI
TDF/3TC/EFV* NNRTI + dual NRTI
LPV/r Boosted PI
RPV/TDF/FTC NNRTI + dual NRTI
Under study
Dolutegravir/ABC/3TC Integrase inhibitor + dual NRTI
Elvitegravir/cobicistat/TDF/FTC Boosted integrase inhibitor + 
dual NRTI 
ATV + RTV (coblister) Boosted PI
Note: *Fixed-dose combinations not available in the United States.
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; 
d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; NNRTI, 
non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase 
inhibitor;  NVP,  nevirapine;  PI,  protease  inhibitor;  RPV,  rilpiverine;  RTV,  ritonavir;   
TDF, tenofovir.
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twice-daily regimens (77% vs 76%, respectively; P = 0.21). 
More recent antiretroviral simplification studies comparing 
once-daily versus twice-daily antiretroviral regimens are 
summarized in Table 2. Patient adherence to treatment 
regimens showed improvement in most of these studies with 
treatment simplification.13,19,22–27 In another study, Airoldi et al 
reported that patients with HIV-RNA , 50 copies/mL on a 
twice-daily or three times-daily regimen were switched to a 
fixed-dose combination of efavirenz/emtricitabine/tenofovir 
and reported better antiretroviral adherence after the switch 
(93.8% vs 96.1%, respectively; P , 0.01).22
In summary, the overall degree of improvement in anti-
retroviral adherence in these recent studies (Table 2) varied 
from modest to significant. Once-daily treatment regimens, 
especially those that are based on single-tablet fixed-dose 
combination formulations, confer the major advantages of 
reduced pill counts and dosing frequencies.19,22–27   Especially 
for patients who may otherwise find it difficult to   follow 
  rigorous dosing schedules, these simplified regimens have 
been shown to improve regimen adherence,   treatment 
  persistence and patient satisfaction in a number of studies. 
These associated benefits apply to all patients on antiretroviral 
regimens, but appear to be especially important in patients 
facing multiple life challenges, such as marginal housing 
or frank homelessness, and/or active injection drug use.13 
A more extensive discussion on the impact of once-daily 
regimens on treatment adherence and persistence has been 
published elsewhere.2
Risks and burdens with once-daily 
antiretroviral regimens?
The convenience of a once-daily antiretroviral regimen 
is appealing, but the pharmacologic consequence of a 
missed dose is greater with a once-daily formulation than 
with a twice-daily regimen. Furthermore, there are clinical 
  scenarios where once daily is not recommended. For 
example, patients with high baseline viral load (.100,000) 
had lower virologic suppression with once-daily dosing 
compared with twice-daily dosing of lopinavir/ritonavir.27 
Once-daily dosing of lopinavir should be avoided in the third 
trimester of pregnancy because this may result in lower drug 
exposure. In patients with genotypic protease inhibitor 
mutations, twice-daily   dosing of boosted protease inhibitor 
(ie, lopinavir/r, darunavir/r) is recommended due to better 
virologic outcome.
While initial pharmacokinetic/dynamic parameters 
suggested that raltegravir may be a once-daily regimen can-
didate, a randomized study of raltegravir 800 mg once daily 
compared with raltegravir 400 mg twice daily, each on a 
  background of tenofovir/emtricitabine in 770 antiretroviral-
naïve patients, demonstrated that 83.2%   taking raltegravir once 
daily versus 88.9% taking   raltegravir twice daily achieved an 
undetectable viral load (,50   copies/mL).24 The treatment out-
come difference of −5.7% (95% CI: −10.7%, −0.83%) did not 
meet the criteria for noninferiority. The observed difference 
was largely driven by patients with high viral load. Among 
those with a viral load .100,000 copies/mL, 74.3% of the 
once-daily group versus 84.2% of the twice-daily group had 
undetectable viral load.24
Finally, clinicians should be aware that the pharmacokinetic 
parameters of once-daily dosing may not be adequate. A once-
daily treatment regimen is usually associated with higher 
maximum plasma concentration and lower trough plasma 
concentrations of the antiretrovirals. The increase in peak 
concentration may result in higher toxicity, as demonstrated 
for boosted protease inhibitors28 and “off-label” use of 
nevirapine immediate-release (2 × 200 mg once daily).29 
Drugs with a short half-life, such as zidovudine, stavudine, and 
the non-boosted protease inhibitors (except atazanavir), are 
not suitable for once-daily administration due to inadequate 
drug concentrations through needed 24-hour period. On the 
other hand, once-daily administration of boosted protease 
inhibitors may not provide adequate trough concentrations 
when the virus shows reduced susceptibility to the drug, such 
as during rescue therapy or in patients with protease inhibitor-
associated mutations. For example, although daily dosing with 
darunavir/r (800/100 mg once daily) is noninferior and even 
superior to lopinavir/r in treatment-naïve patients,30 once-
daily darunavir/r is not recommended in patients with more 
than one darunavir-associated resistance mutation (eg, V11I, 
V32I, L33F, I47V , I50V , I54L, I54M, T74P, L76V , I84V , and 
L89V). The enhanced pharmacokinetic profile achieved with 
twice-daily darunavir/r (600/100 mg twice daily) is required 
to overcome low level darunavir resistance.
Way forward and the corresponding 
research agenda
Antiretroviral nonadherence may result from factors other 
than pill burden or dosing frequency, including: tolerability 
and potential drug interactions of regimen; patient factors, 
such as depression or substance abuse; social factors, such 
as stigma and discrimination; or structural factors (eg, cost, 
drug av  ailability, lack of access to and retention in care, 
lack of ins  urance coverage).31 Therefore, it is important to 
re-em  phasize that cl  inicians’ efforts to improve and sustain 
antiretroviral adherence should not be limited to the choice 
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of once-daily antiretroviral regimen, but they need to include 
social support,32 side effect management,33 substance abuse 
management, depression mana  gement, adherence support 
toolkits (eg, pillbox organizers),34 and other targeted inter-
ventions if needed.35
An emerging perspective is that better adherence associ-
ated with once-daily fixed-dose combination regimens or 
other antiretroviral simplification strategies may reduce HIV 
transmission. Indeed, pre-exposure prophylaxis st  udies in men 
who have sex with men who received tenofovir + emtricitabine 
found a 44% overall reduction of HIV tr  ansmission; and as one 
would expect, the efficacy was higher in adherent patients with 
detectable antiretroviral plasma concentrations.36 Likewise, in 
the CAPRISA 004 trial, which was designed to evaluate the 
effectiveness and safety of tenofovir gel for the prevention of 
HIV infection in women, application of 1% tenofovir vaginal 
gel reduced HIV incidence by 39% and by 45% with high-
level gel adherence (defined as .80%).37
In the era of pay-for-patient-performance initiatives, 
rigorous cost-benefit analysis of regimen simplification studies 
will be important. Using this approach will bring added value 
to the underlying medical knowledge base, policy makers, and 
stakeholders if once-daily regimens with directly observed 
therapy are cost-effective when compared with the total health 
care costs for patients who are not virologically suppressed on 
self-administered twice-daily regimens. A key concern that is 
generating interest from both patients and payers is the overall 
cost associated with once-daily versus twice-daily   dosing 
regimens, especially in the life-long treatment for chronic 
HIV infection. With lamivudine coming off patent soon, the 
drug cost of a once-daily dosing of lamivudine, tenofovir, 
and efavirenz will likely be lower compared with once-daily 
  dosing of a fixed-dose combination of efavirenz, emtricitabine, 
and tenofovir (Atripla®). Payer and governmental agencies 
will need to decide if the benefits of fixed-dose combinations 
are worth the higher drug cost. Have the impact on antiretro-
viral adherence and virologic outcomes as well as the direct 
and indirect costs associated with each treatment paradigm 
been rigorously compared? Not to our knowledge, and such 
research is critically needed to guide clinical and policy 
decision-  making. Of note, a recent evaluation of the effect of 
antiretroviral regimen adherence on direct health care costs 
demonstrated that high adherence to antiretroviral regimens 
was associated with lower mean monthly costs of direct health 
care, with the greatest savings seen in hospitalization costs.38
On a global scale, country-specific pharmacoeconomic 
analyses should address the cost-effectiveness of interventions 
to improve antiretroviral regimen adherence. These analyses 
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should include overall global patient costs (ie, not only the 
actual direct costs of different formulations for each drug), 
but also related costs associated with lesser adherence to 
antiretroviral treatment regimens. Total patient costs should 
include the additional health care costs related to managing 
adverse consequences resulting from poor regimen adherence 
(eg, hospitalization with an opportunistic infection) and non-
medical costs, such as social services. Finally, this assessment 
should also include expenses associated with the design of new 
antiretroviral regimens (eg, new genotypic and phenotypic 
virologic testing if applicable) if the original regimen fails.
Country-specific pharmacoeconomic analyses should 
address prospective investigations of the long-term benefits of 
better antiretroviral regimen adherence, the resulting improve-
ments in overall patient outcomes and associated costs,38 
and the cost-effectiveness of simple, reliable, and validated 
interventions to improve antiretroviral regimen adherence.39,40 
Taken together, these analyses will allow the comprehensive 
costs of current antiretroviral regimens to be compared with 
the comprehensive patient costs associated with simplified 
antiretroviral regimens, facilitating evidence-based decision-
making for individual countries and patient groups.
Conclusion
Simplification of antiretroviral treatment is evolving and 
remains an important strategy to improve the long-term 
  management of HIV-infected patients. This can be achieved 
by the development of once-daily fixed-dose combination 
formulations and by new drugs with improved pharmacoki-
netic characteristics. Available evidence demonstrates better 
treatment adherence with once-daily fixed-dose combination 
regimens, especially in patient populations who are more 
likely to be noncompliant with their regimens; however, 
this strategy is suitable for selected antiretrovirals and under 
conditions where the virus shows sufficient susceptibility 
to the specific antiretrovirals in the fixed-dose combination 
under consideration. Clinicians’ efforts to improve and sus-
tain patient adherence should not be limited to the choice 
of a once-daily regimen, but also need to be comprehensive 
in addressing the specific patient’s needs and preferences. 
Further research will be necessary to establish the benefits of 
once-daily antiretroviral dosing strategies in various patient 
populations, including better adherence, reduction of HIV 
transmission, and comprehensive cost-effectiveness.
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